XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB) has released an update.
XTL Biopharmaceuticals Ltd. successfully held its Annual and Extraordinary General Meeting, with shareholders approving all proposals including the appointment of auditors, re-election of board members, and terms of the acquisition of The Social Proxy Ltd. The company, focusing on developing treatments for Lupus and Sjögren’s Syndrome, is traded on both the Nasdaq and Tel Aviv Stock Exchange and is seeking strategic partnerships for clinical trials while expanding its portfolio.
For further insights into XTLB stock, check out TipRanks’ Stock Analysis page.
